COVID-19 and geriatric population: from pathophysiology to clinical perspectives.
COVID-19
SARS-CoV-2
aged
elderly
geriatric
Journal
Hormone molecular biology and clinical investigation
ISSN: 1868-1891
Titre abrégé: Horm Mol Biol Clin Investig
Pays: Germany
ID NLM: 101538885
Informations de publication
Date de publication:
04 Feb 2021
04 Feb 2021
Historique:
received:
29
07
2020
accepted:
19
01
2021
pubmed:
6
2
2021
medline:
10
4
2021
entrez:
5
2
2021
Statut:
epublish
Résumé
The COVID-19 pandemic has not only led to a worldwide socio-economic depression, but has also had the highest health impact on the geriatric population. Elderly population, due to various reasons such as low immunity, pre-existing co-morbidities such as hypertension, cardiovascular diseases or diabetes, are obviously predisposed to develop severe infections and exhibit a high mortality rate. This is because of many reasons which include the atypical presentation in the geriatric population which might have led to diagnostic delay. As per the WHO guidelines to perform RT-PCR only on the symptomatic individuals, a very small portion of individuals were tested, leaving a fraction of population undiagnosed. Therefore, there remained a chance that many asymptomatic individuals such caregivers, healthcare professionals, family members were undiagnosed and might have carried this virus to the geriatric patients. Also, many countries were not prepared to handle the burden on their healthcare system which included sudden increased demand of ICU beds, mechanical ventilation etc. As a result, they had to make decision on who to be admitted. Atypical presentation in geriatric population may include afebrile or low-grade fever, absence of cough, malaise, muscle pains, dyspnoea etc. Geriatric population shows a more severe type of pneumonia, significantly higher number of neutrophils and C-reactive protein, less lymphocytes and a higher proportion of multiple lobe involvement. Extreme social suppression during COVID-19 pandemic has increased the risk of mental and physical adverse effects that has made older adults more vulnerable to depression and anxiety.
Identifiants
pubmed: 33544506
pii: hmbci-2020-0053
doi: 10.1515/hmbci-2020-0053
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-98Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Li, Q, Guan, X, Wu, P, Wang, X, Zhou, L, Tong, Y, et al.. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199–207.
Chan, JF, Yuan, S, Kok, KH, To, KK, Chu, H, Yang, J, et al.. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514–23. https://doi.org/10.1016/s0140-6736(20)30154-9.
Guo, YR, Cao, QD, Hong, ZS, Tan, YY, Chen, SD, Jin, HJ, et al.. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research 2020;7:1. https://doi.org/10.1186/s40779-020-00240-0.
Sahu, KK, Mishra, AK, Lal, A, Sahu, SA. India fights back: COVID-19 pandemic. Heart Lung 2020;49:446–8.
Singhal, T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020:1–6.
Kochi, AN, Tagliari, AP, Forleo, GB, Fassini, GM, Tondo, C. Cardiac and arrhythmic complications in patients with COVID‐19. J Cardiovasc Electrophysiol 2020;31:1003–8. https://doi.org/10.1111/jce.14479.
Zhu, H, Rhee, JW, Cheng, P, Waliany, S, Chang, A, Witteles, RM, et al.. Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response. Curr Cardiol Rep 2020;22:1–9. https://doi.org/10.1007/s11886-020-01302-4.
Payus, AO, Lin, CL, Noh, MM, Jeffree, MS, Ali, RA. SARS-CoV-2 infection of the nervous system: a review of the literature on neurological involvement in novel coronavirus disease (COVID-19). Bosn J Basic Med Sci 2020. https://doi.org/10.17305/bjbms.2020.4860.
Padhi, A, Kumar, S, Gupta, E, Saxena, SK. Laboratory diagnosis of novel coronavirus disease 2019 (COVID-19) infection. Singapore: Springer; 2020:95–107 pp.
Pormohammad, A, Ghorbani, S, Baradaran, B, Khatami, A, Turner, R, Mansournia, MA, et al.. Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: a systematic review and meta-analysis. Microb Pathog 2020:104390. https://doi.org/10.1016/j.micpath.2020.104390.
Mousavizadeh, L, Ghasemi, S. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect 2020. https://doi.org/10.1016/j.jmii.2020.03.022 [Epub ahead of print].
Liu, YC, Kuo, RL, Shih, SR. COVID-19: the first documented coronavirus pandemic in history. Biomed J 2020;43:328–33.
Callaway, E, Ledford, H, Mallapaty, S. Six months of coronavirus: the mysteries scientists are still racing to solve. Nature 2020;583:178–9. https://doi.org/10.1038/d41586-020-01989-z.
Soy, M, Keser, G, Atagündüz, P, Tabak, F, Atagündüz, I, Kayhan, S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 2020:1. https://doi.org/10.1007/s10067-020-05190-5.
Henderson, LA, Canna, SW, Schulert, GS, Volpi, S, Lee, PY, Kernan, KF, et al.. On the alert for cytokine storm: immunopathology in COVID‐19. Arthritis Rheumatol 2020;72:1059–63.
Ye, Q, Wang, B, Mao, J. The pathogenesis and treatment of theCytokine Storm’in COVID-19. J Infect 2020;80:607–13. https://doi.org/10.1016/j.jinf.2020.03.037.
Connors, JM, Levy, JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135:2033–40. https://doi.org/10.1182/blood.2020006000.
Rokkas, T. Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis. Ann Gastroenterol 2020;33:355. https://doi.org/10.20524/aog.2020.0506.
Su, S, Shen, J, Zhu, L, Qiu, Y, He, JS, Tan, JY, et al.. COVID19? Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol 2020;13:1756284820934626. https://doi.org/10.1177/1756284820934626.
Li, LY, Wu, W, Chen, S, Gu, JW, Li, XL, Song, HJ, et al.. Digestive system involvement of novel coronavirus infection: prevention and control infection from a gastroenterology perspective. J Digest Dis 2020;21:199–204. https://doi.org/10.1111/1751-2980.12862.
Baig, AM, Khaleeq, A, Ali, U, Syeda, H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020;11:995–8. https://doi.org/10.1021/acschemneuro.0c00122.
Volpato, S, Landi, F, Incalzi, RA. A frail health care system for an old population: lesson form the COVID-19 outbreak in Italy. J Gerontol: Ser A 2020;75:e126–7.
Mallapaty, S. The coronavirus is most deadly if you are older and male - new data reveal the risks. Nature 2020;585:16–7. https://doi.org/10.1038/d41586-020-02483-2.
D’Adamo, H, Yoshikawa, T, Ouslander, JG. Coronavirus disease 2019 in geriatrics and long‐term care: the ABCDs of COVID‐19. J Am Geriatr Soc 2020;68:91. https://doi.org/10.1111/jgs.16445.
Boccardi, V, Ruggiero, C, Mecocci, P. COVID-19: A geriatric emergency. Geriatrics 2020;5:24.
Tay, HS, Harwood, R. Atypical presentation of COVID-19 in a frail older person. Age Ageing 2020;49:523–4.
Liu, K, Chen, Y, Lin, R, Han, K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect 2020;80:e14–8.
Nicol, GE, Piccirillo, JF, Mulsant, BH, Lenze, EJ. Action at a distance: geriatric research during a pandemic. J Am Geriatr Soc 2020;68:922–5.
Armitage, R, Nellums, LB. COVID-19 and the consequences of isolating the elderly. The Lancet Public Health 2020;5:e256. https://doi.org/10.1016/s2468-2667(20)30061-x.
World Health Organization. COVID-19 vaccines. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines [Accessed 18 Jan 2021].
Kaur, SP, Gupta, V. COVID-19 Vaccine: a comprehensive status report. Virus Res 2020;288:198114. https://doi.org/10.1016/j.virusres.2020.198114.
World Health Organization. Who can take the Pfizer-BioNTech COVID-19 vaccine? Available from: https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine [Accessed 18 Jan 2021].
Koff, WC, Williams, MA. Covid-19 and immunity in aging populations—a new research agenda. N Engl J Med 2020;383:804–5.
Jean, SS, Lee, PI, Hsueh, PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect 2020.
Mitjà, O, Clotet, B. Use of antiviral drugs to reduce COVID-19 transmission. The Lancet Global Health 2020;8:e639–40. https://doi.org/10.1016/s2214-109x(20)30114-5.
Şimşek, YS, Ünal, S. Antiviral treatment of COVID-19. Turk Med J Sci 2020;50:611–9.
Bloch, EM, Shoham, S, Casadevall, A, Sachais, BS, Shaz, B, Winters, JL, et al.. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757–65. https://doi.org/10.1172/jci138745.
Rajendran, K, Narayanasamy, K, Rangarajan, J, Rathinam, J, Natarajan, M, Ramachandran, A. Convalescent plasma transfusion for the treatment of COVID‐19: systematic review. J Med Virol 2020;92:1475–83.